Adial Pharmaceuticals, Inc. acquires Azora Therapeutics, Inc. (2026)

Deal facts

Buyer: Adial Pharmaceuticals, Inc.
Target: Azora Therapeutics, Inc.
Deal value: Not disclosed
Announced: 11 June 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

What we know

Adial Pharmaceuticals, Inc. has agreed to acquire Azora Therapeutics, Inc. in a strategic acquisition within the Healthcare sector. The transaction was announced and completed on 11 June 2026, with both entities operating from the United States. Consideration for the deal was provided entirely through shares, although the specific value of the transaction was not disclosed to the public. This structure allows the acquiring company to integrate the target without an immediate cash outflow, while the target shareholders receive equity in the combined entity.

The deal represents a significant consolidation for the US healthcare market, bringing together two distinct pharmaceutical entities under a single ownership structure. As the transaction has already been completed, the integration phase is now underway. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

11 Jun 2026CompletedClosed
Adial Pharmaceuticals, Inc. completes acquisition of Azora Therapeutics, Inc.
Item 1.01 - Entry into a Material Definitive Agreement. Agreement and Plan of Merger On June 11, 2026, Adial Pharmaceuticals, Inc., a Delaware corporation (the “ Company ” or “ Adial ”), acquired Azora Therapeutics, Inc., a Delaware corporation (“ Azora ”), in accordance with the terms of the Agreement and Plan of Merger, dated June 11, 2026 (the “ Merger Agreement ”), by and among the Company, Ad
Source

OpinionExit Mode editorial

We see a clear signal in the completed strategic acquisition of Azora Therapeutics by Adial Pharmaceuticals. Announced on 11 June 2026, this deal closes a chapter for two US-based healthcare entities without any cash changing hands. The entire consideration is structured as a share exchange, meaning the founders and shareholders of Azora now hold a direct stake in the combined entity rather than walking away with immediate liquidity. This is a classic consolidation move within the biotech sector where scale and pipeline depth often matter more than short-term cash reserves.

For the SME founder reading this, the mechanics here are instructive. When a deal is priced purely in shares, the risk profile shifts entirely from execution of the transaction to the future performance of the buyer. There is no escrow to protect against post-close surprises and no earn-out to bridge valuation gaps because the price is effectively set by the market value of the buyer's stock at completion. In the US healthcare space, this often invites scrutiny from the CMA or equivalent antitrust bodies if the combined entity holds significant market share, though the primary regulatory hurdle in this specific context is likely the standard merger control review required for any change of control in a regulated industry. The absence of a disclosed value figure further suggests that the parties prioritised speed and certainty over public valuation debates.

We think this structure reflects a pragmatic approach to M&A in a sector where cash is often scarce and R&D needs are relentless. By opting for a share swap, Adial preserves its cash reserves for development while offering Azora's team a continued role in the business. However, this creates a direct dependency on the buyer's share price trajectory. The deal is already completed, so the market has had its say on the immediate terms. The real test for the former Azora leadership will be managing their new equity position without the safety net of a cash payout.

Your immediate action this week is to review your current term sheet or LOI to identify if your proposed consideration is 100 per cent equity. If it is, demand a detailed liquidity analysis of the buyer's stock, including any lock-up periods or vesting schedules that could prevent you from selling your new shares immediately after completion.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Adial Pharmaceuticals, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history